Dr. Angelos Stergiou, President and CEO of SELLAS Life Sciences Group, a late-stage clinical biopharmaceutical company discusses their Phase 3 lead asset, Galinpepimut-S (GPS) a novel immunotherapy that helps to prolong overall survival for cancer patients who are in remission as a monotherapy. He talks about the various indications that GPS targets and the company’s focus on the Wilms Tumor 1 (WT1) antigen and why they are the most advanced company working on this in the space.
Dr. Angelos M. Stergiou is the founder, President and Chief Executive Officer of SELLAS Life Sciences Group, Inc. Prior to founding SELLAS in 2012, Dr. Stergiou co-founded Genesis Life Sciences, Ltd. (now Genesis Research), a boutique health economics and pricing-reimbursement and health access company, where he served as President and Chief Operating Officer from 2009 to 2011. From 2002 to 2009, Dr. Stergiou held international positions of increasing responsibility in pharmaceutical and biotechnology companies, including PAION AG, Accentia Biopharmaceuticals, BioVest International, Analytica International and Anavex Life Sciences. During this time, Dr. Stergiou held roles ranging from Head of Clinical Research and Vice President of Product Development, Chief Medical Officer and Chief Operations Officer with responsibility for medical affairs, clinical research and development, pharmacovigilance, clinical operations, project management, regulatory affairs, biostatistics and chemistry, manufacturing and controls (CMC). Dr. Stergiou has led and overseen research endeavors in all phases of clinical development across many indications, including CNS, cardiovascular, oncology, respiratory and autoimmune diseases, and has a broad understanding of all aspects of clinical development and medical affairs. He has designed and implemented research projects in the United States, Canada, Australia, Japan and Europe. Dr. Stergiou was a member of the joint steering and oversight committee of PAION AG with Forest Laboratories, Inc. He also led the Phase 3 development of a therapeutic cancer vaccine, BiovaxID, into completion which was presented at the American Society of Clinical Oncology plenary session in 2009 and also holds a patent on the technology. Dr. Stergiou holds a Doctor of Medicine from the U.S. American Institute of Medicine and a Doctor of Science (honoris causa) degree from Kentucky Wesleyan College, and received his Bachelor of Sciences degree from Kentucky Wesleyan College with a major in Pre-Medicine, Biology and Chemistry. Dr. Stergiou is a member of the Board of Trustees at Kentucky Wesleyan College, a Fellow of the Royal Society of Medicine (UK – ID:00707077), an active member of the World Medical Association, a member of the American Academy of Physicians in Clinical Research, a member of the Association of Clinical Research Professionals, and a member of the New York Academy of Sciences.